The ALKBH5 inhibitor ALK-04 effectively sensitized melanoma cells to anti-PD-1 blockade, as ALKBH5 attenuated immunotherapy responses via regulating lactate content and immunosuppressive cell infiltration in the TME.404 Selberg et al. discovred two compouds, 2-[1-hydroxy-2-oxo-2-phenylethyl]sulfanyl acetic acid and 4-[furan-2-yl]methyl amino-1,2-diazinane-3,6-dione, demonstrated cancer-cell-type-selective antiproliferative effects in selected leukemia cell lines.417 Targeting SAM binding sites, adenosine was first identified as METTL3 inhibitors. This evidence concerns the gene ALKBH5 and melanoma.